de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development.Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Wang A.
Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure.US Food and Drug Administration. FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation. Published March 14, 2019. Accessed October 30, 2021. www.fda.gov/news-events/press-announcements/fda-approves-new-indication-valve-repair-device-treat-certain-heart-failure-patients-mitral.
Obadia JF, Messika-Zeitoun D, Leurent G, et al; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation.Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group; ESC Scientific Document Group. 2021 ESC/EACTS guidelines for the management of valvular heart disease.Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT Trials.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity. Department of Surgery